Home
Resources
Publications
Efficacy and Tolerability of Vildagliptin as an Add-On to Glimepiride in Japanese Patients With Type 2 Diabetes Mellitus

Efficacy and Tolerability of Vildagliptin as an Add-On to Glimepiride in Japanese Patients With Type 2 Diabetes Mellitus

Masatoshi Kikuchi, Masakazu Haneda, Daisuke Koya, Kazuyuki Tobe, Yukiko Onishi, Andre Couturier, Nobuyuki Mimori, Yoko Inaba, Matthew Goodman

Diabetes Res Clin Pract. 2010 Sep;89(3):216-23.

PMID: 20537746

Abstract:

Aim:
To investigate the efficacy and tolerability of vildagliptin, a potent and selective dipeptidyl peptidase-4 inhibitor, as add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus (T2DM) who were inadequately controlled.
Methods:
This 12-week, randomized, double-blind, placebo-controlled study compared vildagliptin 50mg twice-daily (n=102) with placebo (n=100) when added to a stable dose of glimepiride (>or=1mg/d).
Results:
Treatment groups were balanced at baseline (glycosylated hemoglobin [HbA(1c)], 7.9%; fasting plasma glucose, 163.8 mg/dL). During treatment HbA(1c) decreased progressively with vildagliptin, but remained unchanged with placebo. The adjusted mean change (AMDelta) at endpoint was -1.0+/-0.1 and -0.1+/-0.1% in vildagliptin- and placebo-treated patients (between-group Delta=-1.0+/-0.1%, P<0.001). A greater proportion of vildagliptin-treated patients had HbA(1c) Conclusion:
Vildagliptin is effective and well tolerated as an add-on to glimepiride in Japanese patients with T2DM.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP791104626	Glimepiride Related Compound D		791104-62-6	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: